SCHEMBL2799465

SCHEMBL2799465

Cc1ccc2[nH]c(-c3ccccc3)cc(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 9/20 1.00
▸ KDM4E B2RXH2 7/20 1.00
▸ LMNA P02545 6/20 1.00
▸ RAB9A P51151 6/20 1.00
▸ NPC1 O15118 5/20 1.00
▸ SMN1; SMN2 Q16637 5/20 1.00
▸ MAPT P10636 2/20 1.00
▸ TP53 P04637 2/20 1.00
▸ HSD17B10 Q99714 2/20 1.00
▸ ALDH1A1 P00352 8/20 0.82
▸ MEN1 O00255 3/20 0.82
▸ KMT2A Q03164 3/20 0.82
▸ MAPK1 P28482 1/20 0.82
▸ CTSV O60911 2/20 0.69
▸ CTSL P07711 2/20 0.69
▸ TUBB4A P04350 2/20 0.68
▸ TUBB P07437 2/20 0.68
▸ TUBA3C P0DPH7 2/20 0.68
▸ TUBA1B P68363 2/20 0.68
▸ TUBA4A P68366 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13232494 0.89 HPGD (0.80) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL30935699 0.87 HPGD (0.77) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL2630603 0.83 HPGD (0.76) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL6534180 0.82 HPGD (1.00) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL30935678 0.82 HPGD (1.00) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL6688057 0.82 HPGD (1.00) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL367268 0.81 HPGD (1.00) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL29411863 0.81 HPGD (1.00) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL1273139 0.81 HPGD (0.68) HPGDKDM4ELMNARAB9ANPC1
SCHEMBL8980204 0.81 PDE10A (0.73) HPGDKDM4ELMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118108771-A Method for preparing quinolone compound by high-efficiency catalysis of pyridine palladium 安康学院 2024-05-31 — — CN disclosed
US-9029394-B2 2-phenyl-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-12 — — US disclosed
US-9029394-B2 2-phenyl-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-12 — — US disclosed
US-9029394-B2 2-phenyl-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-12 — — US disclosed
US-9023867-B2 Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-9023866-B2 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-9023866-B2 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-9023866-B2 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-9023867-B2 Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-9023867-B2 Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2015-05-05 — — US disclosed
US-8440692-B2 Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents CHINA MEDICAL UNIVERSITY (TW) 2013-05-14 — — US disclosed
US-20130102627-A1 Acridines As Inhibitors Of Haspin And DYRK Kinases THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-04-25 — — US disclosed
EP-2468747-A1 2-Selenophene-4-quinolones as anticancer agents China Medical University (TW) 2012-06-27 — — EP disclosed
EP-2468747-A1 2-Selenophene-4-quinolones as anticancer agents China Medical University (TW) 2012-06-27 — — EP disclosed
EP-2455369-A1 Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents China Medical University (TW) 2012-05-23 — — EP disclosed
EP-2455369-A1 Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents China Medical University (TW) 2012-05-23 — — EP disclosed
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2010-07-01 — — US disclosed
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2010-07-01 — — US disclosed
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2010-07-01 — — US disclosed
WO-2008070176-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS CHINA MEDICAL UNIVERSITY (TW) 2008-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168064-A1 NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS DHX30, SLC20A2, DDX20 HPGD 1886/4885KDM4E 2310/4885LMNA 4383/4885
US-20130102627-A1 Acridines As Inhibitors Of Haspin And DYRK Kinases HASPIN, MAP3K6, DAPK2 HPGD 1984/4885KDM4E 3446/4885LMNA 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback